GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » Equity-to-Asset

RGDXQ (Response Genetics) Equity-to-Asset : -0.46 (As of Mar. 2015)


View and export this data going back to 2007. Start your Free Trial

What is Response Genetics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Response Genetics's Total Stockholders Equity for the quarter that ended in Mar. 2015 was $-4.94 Mil. Response Genetics's Total Assets for the quarter that ended in Mar. 2015 was $10.78 Mil. Therefore, Response Genetics's Equity to Asset Ratio for the quarter that ended in Mar. 2015 was -0.46.

The historical rank and industry rank for Response Genetics's Equity-to-Asset or its related term are showing as below:

RGDXQ's Equity-to-Asset is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.59
* Ranked among companies with meaningful Equity-to-Asset only.

Response Genetics Equity-to-Asset Historical Data

The historical data trend for Response Genetics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Response Genetics Equity-to-Asset Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.78 -0.03 0.32 0.73 0.68

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.12 0.73 -0.46 0.68

Competitive Comparison of Response Genetics's Equity-to-Asset

For the Diagnostics & Research subindustry, Response Genetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Response Genetics's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Response Genetics's Equity-to-Asset falls into.



Response Genetics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Response Genetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Equity to Asset (A: Dec. 2015 )=Total Stockholders Equity/Total Assets
=33.017/48.884
=0.68

Response Genetics's Equity to Asset Ratio for the quarter that ended in Mar. 2015 is calculated as

Equity to Asset (Q: Mar. 2015 )=Total Stockholders Equity/Total Assets
=-4.937/10.778
=-0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Response Genetics  (OTCPK:RGDXQ) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Response Genetics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Response Genetics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Response Genetics Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Executives
Roberto Mignone 10 percent owner C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber director 15 TROTTERS LANE, MONROE CT 06468
Sam Chawla director 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris officer: Vice President and CFO 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya director C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna director, officer: Chief Executive Officer 4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor 12-14-2009